Adaptive has identified and characterized ultra-potent, neutralizing antibodies to SARS-CoV-2. Our antibodies can be considered for development as either differentiated monoclonal antibodies or as synergistic antibody cocktail to treat or prevent COVID-19.
Beyond COVID-19, Adaptive is exploring applications of TruAB discovery in other diseases, including autoimmunity.